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Process of care for carotid endarterectomy:
Perioperative medical management
Michael C. Stoner, MD, and Dorian J. deFreitas, MD, Greenville, NC
Carotid endarterectomy (CEA) has been repeatedly described as a safe and efficacious procedure to provide a stroke-risk
reduction benefit in both symptomatic and asymptomatic cases. Contemporary outcomes are acceptable using the
large-scale randomized trials as a metric of success. Class I and II data can be applied to improve the care process of
patients undergoing CEA. Myocardial infarction remains the most significant nonstroke complication; however, there is
no significant benefit to noninvasive stress testing in patients with clinically stable disease. Perioperative -blockade may
offer up to a 10-fold reduction in the rate of perioperative myocardial infarction, but deleterious effects are attributable
to high-dose regimens. Angiotensin blockade has been shown to reduce cardiovascular mortality in patients with
atherosclerosis by up to 25%, although few studies have examined these agents directly in carotid surgery patients. Statins
are beneficial to patients undergoing CEA with trials demonstrating up to a 3% absolute reduction in the incidence of
stroke following CEA. Aspirin therapy is associated with an up to 7% absolute reduction in early stroke following CEA;
however, the efficacy of combination or high-dose antiplatelet therapy remains ill-defined. A treatment strategy that
involves perioperative medical optimization is likely to improve surgical outcomes and long-term cardiovascular risk for
patients undergoing CEA. (J Vasc Surg 2010;52:223-31.)Carotid endarterectomy (CEA) has been well estab-
lished as the preferred treatment for flow-limiting stenoses
of the carotid artery in both symptomatic and asymptom-
atic patients. The large-scale randomized trials of the early
1990s have established the stroke/death rate metrics that
are widely cited today.1-4 Achievement of these outcomes
has been replicated outside of clinical trials, and two recent
large-scale database studies in fact compare favorably to
these data5,6 and are the expectation with CEA across a
spectrum of hospitals and surgeons.7 While a perfect surgi-
cal operation has long been recognized by vascular sur-
geons as the sine qua non for minimizing complications,
certain care processes, some surgery related and others
referable to perioperative medical therapies have been dem-
onstrated to significantly influence at least short-term out-
comes of carotid surgery. A recent review of over 20,000
Medicare patients indicated suboptimal rates of major
adverse events in asymptomatic patients, presumptively
related to the absence of antiplatelet therapy and patch
reconstruction.8
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doi:10.1016/j.jvs.2009.10.125Cardiac adverse events represent a significant portion of
the nonneurologic complications associated with surgical
carotid revascularization. Because CEA represents a risk-
reduction procedure, all attempts should be made to im-
prove the safety profile of the procedure. The purpose of
this article is to review methods for perioperative care
improvement of patients undergoing CEA and to review
treatment strategies to reduce both neurologic and non-
neurologic adverse events (Table I).
CARDIAC-RELATED EVENTS AFTER CEA
About a decade after the landmark 1954 operation by
Eastcott and collegues,9 DeBakey and other authors de-
scribedmyocardial infarction (MI) as the principle nonneuro-
logic immediate and long-term adverse event associated
with CEA.10-12 In addition, longitudinal studies after CEA
indicated that associated coronary artery disease was the
principle cause of late mortality in patients with or without
overt cardiac disease at the time of endarterectomy.13 Sub-
sequently, the association between carotid and coronary
disease has been repeatedly demonstrated. Anatomical cor-
onary artery disease has been demonstrated in 73% of
patients undergoing carotid revascularization with up to
26% having severe correctable coronary artery disease.14,15
In contemporary practice, the incidence of Q-wave MI
following CEA is typically less than 2% but represents
almost half of the major adverse events associated with
carotid revascularization in asymptomatic patients.4,5,16,17The incidence of minimal myocardial injury may be higher.
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noted to be 6.7% in the surgical arm of the Stenting and
Angioplasty with Protection in Patients at High Risk for
Endarterectomy (SAPPHIRE) trial,18 although this study
stands as an outlier with respect to preoperative cardiac
events when compared to the bulk of the literature. While
the clinical significance of this finding to the individual
patient is nebulous, these data demonstrates the significant
atherosclerotic disease burden in patients undergoing
CEA.
CARDIAC RISK STRATIFICATION
Much of the prodigious literature on cardiac risk strat-
ification was developed in vascular surgery patients. The
ground-breaking work looking into noninvasive physio-
logic testing (nuclear stress test) to predict cardiac events
was reported in a series of vascular surgery patients.19
Decades ago, it was realized that postoperative MI risk
following CEA was directly associated with a history of
angina symptoms.20 However, despite a prevalence of an-
atomical coronary disease as high as 73%, the past literature
did not support coronary revascularization in patients with
either stable angina or occult disease.21 More recent re-
views have demonstrated that prophylactic myocardial re-
vascularization has only an anecdotal benefit and has not
been demonstrated to be of benefit in any randomized
trial.22 The randomized CARP trial failed to demonstrate a
benefit to prophylactic coronary revascularization in pa-
Table I. Summary of pharmacotherapy strategies for
patients undergoing carotid endarterectomy
Strategy Key points
-blockade ● Reduces myocardial injury rates following
surgery in appropriately selected patients
● Low-risk patients likely do not derive a
benefit if not already on a -blocker
● May be associated with adverse events at
higher doses or if used indiscriminately
ACE inhibitor/
ARB
● Associated with improved long-term
survival in patients with peripheral vascular
disease
● Stabilizes carotid plaque and improve vessel
wall biology
● Appropriate long-term agent for patients
without contraindications
Statin ● Reduces acute and long-term stroke risk,
reduces cardiovascular event rate, associated
with long-term survival
● Multiple mechanisms of action including
lipid profile and plaque stabilization
● Reasonable agent for all patient undergoing
vascular surgery
Antiplatelet ● Reduces acute and long-term stroke risk,
reduction in cardiovascular event rate
● Low-dose aspirin efficacious
● No clear benefit to dual therapy or high-
dose therapy in patients undergoing CEA
ACE, Angiotensin-converting enzyme; ARB, angiotensin receptor blocker;
CEA, carotid endarterectomy.tients undergoing elective vascular surgery.23 With theseconsiderations in mind, specific coronary workup is not
routinely recommended in patients undergoing CEA.
Conversely, there is little evidence patients undergoing
coronary artery bypass grafting (CABG) should be rou-
tinely screened for carotid disease preoperatively unless
they fall into a high-risk group (age greater than 65, carotid
bruit or history of cerebrovascular disease).24 There is
evidence that patients who have symptomatic carotid dis-
ease undergoing CABG benefit from CEA. There are lim-
ited high-quality data to support the use of CEA in asymp-
tomatic patients undergoing coronary revascularization.25
The current American College of Cardiology/Amer-
ican Heart Association guidelines consider CEA as an
intermediate-risk surgical procedure. The ACC/AHA guide-
lines provide class I (Table II) data to support noninvasive
stress testing in patients with active cardiac conditions: unsta-
ble coronary syndrome, decompensated heart failure, signifi-
cant arrhythmias or severe valvular disease.26
Other indications for noninvasive testing may be ap-
propriate in select patients but are not supported with class
I data. The DECREASE (Dutch Echocardiographic Car-
diac Risk Evaluation Applying Stress Echo)-II study
showed that if patients were appropriately -blocked, the
perioperative cardiac event rate was reduced regardless of
preoperative noninvasive testing. The cardiac death andMI
rate at 30 days in patients with no testing was 1.8% vs 2.3%;
odds ratio (OR) 0.78, 95% confidence interval (CI) 0.28-
2.1. Cardiac testing delayed surgery for more than 3
weeks.27 Based on the lack of data to support coronary
revascularization to reduce myocardial injury risk, there are
likely few cases which will benefit from expanded indica-
tions. Medical optimization of myocardial risk remains the
cornerstone of treatment for patients undergoing carotid
endarterectomy.
-BLOCKADE
-adrenergic receptor antagonists (-blockers, -
blockers) were originally brought to clinical fruition in the
1960s and have been used for a variety of approved indica-
tions including angina pectoris, hypertensive control, car-
Table II. Classification of recommendations
Classification of Recommendations
Class I Conditions for which there is evidence for and/or
general agreement that the procedure or
treatments is beneficial, useful, and effective.
Class II Conditions for which there is conflicting evidence
and/or divergence of opinion about the
usefulness/efficacy of a procedure or treatment.
Class IIa Weight of evidence/opinion is in favor of usefulness/
efficacy.
Class IIb Usefulness/efficacy is less well established by
evidence/opinion.
Class III Condition for which there is evidence and/or general
agreement that the procedure/treatment is not
useful/effective, and in some cases may be harmful.diac arrhythmia management, postcoronary revasculariza-
olol a
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classically described mechanism of action is a sympatholytic
one, with a resultant negative inotropic and chronotropic
effect. -blockade also leads to a decreased production of
renin, which provides an antihypertensive effect. Further-
more, a reduction of sympathetic nervous system activity
has been described for agents that cross the blood-brain
barrier.
Perioperative -blockade has become standard therapy
in the prevention of MI in patients undergoing vascular
surgery. This enthusiasm arose after two landmark publica-
tions showed a significant improvement in cardiovascular
complications and mortality in patients undergoing non-
cardiac vascular surgery. Mangano et al randomized 200
patients to receive atenolol or placebo in the perioperative
period. It was surmised that the prevention of cardiac
deaths in the first 6 to 8 months led to a survival advantage
at 2 years.29 Poldermans’ study randomized patients to
bisoprolol or standard of care in patients undergoing vas-
cular surgery. This study showed a 10-fold reduction in the
perioperative cardiovascular event rate among the patients
who received bisoporol.27
A number of follow-up studies have been performed
comparing -blockers with placebo in noncardiac vascular
surgery with mixed results (Table III). Unfortunately, the
dramatic benefits seen in the studies cited above have not
been universally reproduced. The POISE trial looked at
8351 patients who received a single preoperative does of
100 mg of extended-release metoprolol followed by 200
mg daily for 30 days.30 There were 4174 patients in the
treatment arm and 4177 patients in the placebo group. The
rate of MI was lower in the treatment group vs the placebo
group (4.2% vs 5.7%, P  .0017). However, there were
more deaths in the metoprolol group than in the placebo
group (3.1% vs 2.3%, P .0317). It is important to note that
clinically significant hypotension and bradycardia was higher
in the metoprolol group. The relatively higher doses of meto-
prolol used in this studymay have caused some adverse events
and warns against overly aggressive -blockade.
A recent meta-analysis of 33 randomized controlled
Table III. Selected trials of -blockers compared to place
Study -blocker (n) Comparison (n)
Mangano27 Atenolol (99) Placebo (101) Impr
Poldermans25 Bisoprolol (59) Placebo (53) Deat
3.
DIPOM77 Metoprolol (462) Placebo (459) Perio
by
MaVS Study77 Metoprolol (246) Placebo (250) No b
in
POBBLE78 Metoprolol (55) Placebo (48) Meto
wi
POISE28 Metoprolol (4174) Placebo (4177) Meto
an
hi
DIPOM, Diabetic Postoperative Mortality and Morbidity; MaVS, Metopr
beta-blockade; POISE, Perioperative Ischemic Evaluation.trials has raised a cautionary flag with respect to the ubiq-uitous application of perioperative -blockers.31 In this
study, -blockers were not associated with any significant
reduction in the risk of all-cause mortality, cardiovascular
mortality, or heart failure but did reduce the incidence of
nonfatal MI (odds ratio [OR] 0.65, 95% CI, 0.54-0.79)
and myocardial ischemia (OR 0.36, 0.26-0.50) at the ex-
pense of an increase in nonfatal strokes (OR 2.01, 1.27-
3.68).31 The POISE trial was a major component in this
meta-analysis and therefore caution must be used when
interpreting this data, again because of the relatively high
dose -blockade.30
Heart rate control remains a contentious issue in peri-
operative -blocker management. Trials that allowed for an
increased dose have had overall worse outcomes than those
that did not. The optimal heart rate has not been confirmed
as of yet. Rate control of less than 75 beats per minute was
not significant for efficacy outcomes other than nonfatal
MI.31 These data that do not refute the potential protective
benefits of -blockers do, however, urge caution in their
unfettered use because of potential consequences and an
ill-defined therapeutic window.
Finally, this issue is looming on the horizon as a per-
formance measure despite the unanswered questions about
-blockade including optimal target heart rate, duration,
timing of administration, and efficacy.
The American College of Cardiology and American
Heart Association (ACC/AHA) currently recommend
-blockers for noncardiac surgery (inclusive of CEA) in a
number of clinical situations:26
1. Patients already on therapy or who are having vascular
surgery and have ischemia on preoperative testing or are
taking a -blocker for a defined indication ie, hyperten-
sion, arrhythmia or angina, or other ACC/AHA class I
indication (class I)
2. Patients that are undergoing vascular surgery and have
congestive heart failure or more than one clinical risk
factor for cardiac disease recognized on preoperative
evaluation (class II)
3. Patients undergoing vascular surgery with one or more
patients undergoing noncardiac vascular surgery
Findings
mortality with atenolol 10% vs placebo 21%, P  .019 at 3 years
m cardiac causes of nonfatal MI was improved with bisoprolol
34% P  .001.
tive mortality and cardiac morbidity was not significantly affected
prolol 21% vs 20%; 1.06, 0.8-1.41, in diabetic patients.
t in reducing cardiac events at 30 days and 6 months with an
d rate of hypotension and bradycardia.
ol did not decrease cardiovascular events 32% when compared
cebo 34%; 0.95,0.53-1.66.
ol decreased rate of cardiovascular death, myocardial infarction,
fatal cardiac arrest; 5.8% vs 6.9% P  .04 but at the cost of
verall death and stroke rate.
fter Vascular Surgery; MI, myocardial infarction; POBBLE, Perioperativebo in
oved
h fro
4% vs
pera
meto
enefi
crease
prol
th pla
prol
d non
gher oclinical risk factors for cardiac disease (class IIb)
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-blockers in patients undergoing CEAmay require robust
registry data or larger-scale randomized trials, especially in
light of the confounding trials cited.
ANGIOTENSIN BLOCKADE
Several trials have demonstrated a protective benefit
attributable to agents that block the renin-angiotensin sys-
tem. Angiotensin-converting enzyme was discovered in
1956 by Skeggs and collegues.32 Throughout the 1960s
and 1970s, the biochemical pathways associated with an-
giotensin were elucidated and lead to the approval of
captopril, the first angiotensin-converting enzyme (ACE)
inhibitor, in 1981.
ACE inhibitors impart cardiovascular protection through
a variety of mechanisms, including hypertensive control,
inhibition of platelet aggregation, reduced oxidative stress,
nitric oxide stimulation, and enhancing endogenous fibri-
nolysis.33,34 Furthermore, ACE inhibitors are hypothe-
sized to stabilize vascular plaques, which has a direct impli-
cation on the management of carotid surgery patients.35
The role of ACE in the pathogenesis of inflammation and
rupture of atherosclerotic plaque has led to a myriad of
studies that demonstrated ACE-inhibitor-related carotid
plaque stabilization and improved vessel wall histopathol-
ogy.36 Evolving data indicate that a similar protective ben-
efit can be attributed to angiotensin receptor antagonist,
although the volume of evidence is not as compelling.
Furthermore, there is biologic evidence that angiotensin
blockade coupled with antiplatelet (aspirin) therapy, may
have a synergistic effect on plaque inflammatory markers,
adding a scientific background to the role of multiagent
medical therapy for patients with atherosclerosis.37
The risk reduction attributed to ACE inhibition is
significant. The 2004 HOPE trial was a large-scale trial
designed to examine the effects of ramipril on cardiovascu-
lar events in patients with peripheral arterial occlusive dis-
ease.38 Enrolling over 8000 patients, the study demon-
strated a 25% mortality rate reduction, regardless of
hypertensive status.
The ACC/AHA guidelines recommend treating all
patients with atherosclerotic disease with an ACE inhibitor,
unless there is a contraindication.39 This recommendation
is based on themyocardial risk reduction attributed to these
agents and patients with both coronary and noncoronary
vascular disease. There are no data to date that demon-
strate a stroke-risk reduction in patients undergoing
carotid surgery.
The aforementioned HOPE trial, which enrolled pa-
tients who are at high risk for renal artery stenosis, reported
a 0.12% rate of renal dysfunction following the initiation of
ACE inhibitor therapy, and only 0.5% of patients were
removed from ACE inhibitor therapy long-term because of
renal function deterioration.38 These data contradict the
classical concern that renal artery stenosis is a contraindica-
tion to angiotensin blockade.HMG COA REDUCTASE INHIBITORS (STATINS)
Statins are competitive inhibitors of 3-hydroxy 3-
methylglutaryl coenzyme A (HMG CoA) reductase, the
rate-limiting step in cholesterol biosynthesis. This enzyme
converts HMG-CoA into mevalonic acid, which is a cho-
lesterol precursor. Statin therapy inhibits this pathway
within several cell types, resulting in several therapeutic
benefits in a patient’s lipid profile.40-43 The end result is a
25% to 50% reduction in the level of circulating low-density
lipoprotein (LDL) cholesterol as well as a reduction in the
total cholesterol and triglyceride levels and an elevation in
high-density lipoprotein level (HDL). Rosuvastatin is the
most potent at lowering LDL and triglyceride levels and
raising HDL levels.44
The ability of statins to affect perioperative outcomes
appears to be related to effects other than simply lowering
cholesterol and is referred to as pleiotropic effects. One of the
most important effects in the prevention of perioperative
events is its ability to stabilize atheromatous plaque that is
at risk of rupture resulting in thrombosis or embolism and
acute ischemic events. Patients on statins were also less
likely to have spontaneous cerebral embolization detected
by Doppler during carotid endarterectomy.45 Other non-
lipid profile effects include reduction in levels of C-reactive
protein, inhibition of thrombosis and platelet aggregation,
and nitric oxide-mediated vasodilation.46,47 The expand-
ing list of lipid profile-independent effects strongly sup-
ports the use of statins in patients with peripheral vascular
disease and certainly expands their indication to include all
patients undergoing CEA.
There is a growing body of literature that demonstrates
that statins reduce baseline and perioperativemortality,MI,
and stroke rates in vascular patients.48,49 One of the largest
studies to evaluate the benefit of statins in patients with
CAD or peripheral vascular disease was the heart protection
study. All-cause mortality was significantly reduced over a
5-year period, regardless of the initial cholesterol level, with
1328 (12.9%) deaths among 10,269 allocated simvastatin
vs 1507 (14.7%) among 10,267 allocated placebo; P 
.0003. This protective effect was attributed to a highly
significant 18% relative reduction in the coronary death rate
(5.7% vs 6.9%, P  .0005), a marginally significant reduc-
tion in other vascular deaths (1.9% vs 2.2%, P .07), and a
nonsignificant reduction in nonvascular deaths (5.3% vs
5.6%, P  .4).50
The StaRRS study looked at patients undergoingmajor
vascular surgery including carotid endarterectomy, aortic
surgery, and lower extremity revascularization with the
primary outcomemeasure being death, MI, ischemia, con-
gestive heart failure, and ventricular tachyarrhythmias oc-
curring during the index hospitalization. These data
showed significantly fewer patients reached the primary
endpoint who were taking statins vs patients who were not
on a statin (9.9% vs 16.5%, P  .001). The benefit arose
primarily from a reduction in the rate of MI and congestive
heart failure. With a risk-adjusted model, statins still pro-
vided a protective effect (OR 0.52, CI 0.35-0.76).51 In a
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ized to atorvastatin or placebo for 45 days in the perioper-
ative period. There was a threefold reduction in cardiac
events including death due to a cardiac cause, MI, unstable
angina, and stroke for the patients on atorvastatin. (8% vs
26%).52 The recent SPARCL study has also demonstrated a
benefit to statin therapy in terms of both primary and
secondary stroke prevention, in addition to protection from
major cardiac events.53 In a subgroup analysis, high-dose
atorvastatin imparted a protective, albeit nonsignificant,
benefit on patients with large or small vessel disease-related
stroke and those with transient ischemic attacks.54
Statins have the ability to cause a significant regression
in the carotid intima-media thickness (IMT) as well as IMT
progression rates. IMT is considered a marker of cardiovas-
cular risk, and therefore, one may be able to derive treat-
ment efficacy from this data point. A recent meta-analysis
including over 90,000 patients showed a strong correlation
between LDL lowering and carotid IMT reduction (r 
0.65, P  .04).55
Meta-analyses have shown that statins are beneficial in
the primary and secondary prevention of strokes. A large-
scale study published in 2008 by O’Regan and colleagues
involved an analysis of over 120,000 patients who were
placed in randomized trials to evaluate statin therapy.56
Statin therapy was found to be protective for all stroke
prevention (OR 0.84, CI 0.79-0.91), with a protective
benefit also seen in all-cause mortality, cardiovascular-
related death, and nonhemorrhagic stroke. These data are
backed up by a previous meta-analysis that showed that for
each 10% reduction in LDL cholesterol, there was an
estimated 15.6% reduction in the risk of stroke.55
Current recommendations by the AHA/ACC for peri-
operative statin use for noncardiac vascular surgery are as
follows:26
1. Patients who are on statins preoperatively should have
them continued (class I) and
2. Patients undergoing vascular surgery with or without
clinical risk factors, statin use is reasonable (class II).
There are a number of retrospective studies looking at
statin use and endarterectomy. One of the largest studies
comes from a Canadian administrative database reviewing
carotid endarterectomy in 3360 patients. In patients
treated for symptomatic disease, there was a protective
effect of statin use and perioperative death (OR  0.25,
95% CI 0.07-0.90), perioperative stroke and death (OR 
0.55, 95% CI 0.32-0.95) but not to cardiovascular out-
comes (OR  0.87, 95% CI 0.49-1.54). These protective
effects were largely driven by the symptomatic CEA cases,
with no statistically significant benefit seen in asymptomatic
cases.57
A 10-year review from the Johns Hopkins University
Hospital demonstrated a stroke-risk reduction benefit and
improved periprocedural outcomes.58 Forty-two percent
of the patients were on statin therapy at the time of opera-
tion. Statin use was associated with a significant reduction
in perioperative strokes (1.2% vs 4.5%, P  .01). Whenother confounders were adjusted for, perioperative statin
use was found to reduce the odds of stroke (OR  0.35,
95% CI 0.15-0.85) and death (OR  0.20, 95% CI 0.04-
0.99). There was an insignificant trend toward a lower rate
of perioperative MI.
A second 10-year retrospective study from LaMuraglia
demonstrated an association between statin therapy and
restenosis after CEA.59 The authors examined 2127 carotid
endarterectomy cases and conducted a multivariate analysis
for correlates of both early and late anatomical failure.
Female gender, renal insufficiency, and elevated cholesterol
were all found to be correlates of restenosis. Lipid-lowering
pharmacotherapy was protective for both early and late
recurrent carotid disease. The fact that drug therapy mod-
ulates restenosis at both time points, suggests that statin
therapy has a beneficial effect to both intimal hyperplasia
remodeling and recurrent atherosclerosis after CEA. In a
subsequent study, the same group demonstrated a long-
term survival benefit attributed to drug therapy for hyper-
lipidemia, in a cohort of patients undergoing reoperative
carotid surgery.60
Despite all the benefits of statin therapy, longer-term
compliance after carotid endarterectomy still remains low at
38%.61 Widespread use of statin drugs in this patient pop-
ulation has the potential to improve both neurologic and
nonneurologic adverse events associated with CEA and the
long-term vascular health of this patient population. The
long-term adoption of statin therapy has obvious advan-
tages, especially when evaluated within the context of a
stroke-risk reduction operation.
ANTIPLATELET THERAPY
The causes of stroke after carotid endarterectomy are
multifactorial. Intraoperative stroke tends to follow inad-
vertent technical error such as intraoperative embolization,
carotid dissection, or creation of an intimal flap. Postoper-
ative stroke can be the result of hyperperfusion or hemor-
rhage. Thromboembolic events are the most common
cause of postoperative stroke.62 Transcranial Doppler
(TCD) is a validated method to evaluate patients undergo-
ing carotid endarterectomy. It has been noted that approx-
imately 50% of patients with a sustained high rate of embo-
lization will progress toward thrombotic stroke.63,64
Patients who thrombose after carotid reconstruction may
have a 1- to 2- hour period of increasing cerebral emboli-
zation that precedes the onset of symptoms, that has been
detected with TCD.63
Antithrombotic therapy is an intuitive adjuvant for
patients undergoing carotid endarterectomy. Immediately
following CEA, the endarterectomy bed represents a
thrombogenic nidus. In fact, tagged platelet studies have
demonstrated a decreased platelet adherence to the carotid
endarterectomy site in patients treated with antiplatelet
therapy.65 TCD has been used to demonstrate that incre-
mental doses of Dextran can significantly reduce the rate of
postoperative embolization after CEA.66 Furthermore, the
therapeutic benefit to antiplatelet therapy logically extends
to the coronary vascular bed.
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fit to antiplatelet therapy in patients with coronary and
noncoronary vascular disease. The antithrombotic trialist’s
collaboration looked at randomized controlled trials of
patients on antiplatelet therapy vs control of patients at
high risk for cardiovascular events. They reviewed 287 trials
looking at the endpoints of nonfatal MI, nonfatal stroke,
and death. Antiplatelet therapy reduced combined vascular
events by one-quarter, nonfatal MI by one-third, nonfatal
stroke was reduced by one-quarter, and vascular mortality
by one-sixth. The absolute benefits outweighed the risks of
bleeding.67
The CAPRIE study compared aspirin (325 mg once
daily) vs clopidogrel (75 mg once daily) in reducing the
risks of a composite outcome of stroke, MI, or vascular
death. The patients studied had an atherosclerotic disease
manifested by recent stroke, recent MI or symptomatic
peripheral arterial disease. Over a mean follow-up of almost
2 years, patients taking clopidogrel had an annual 5.32%
risk of stroke, MI, or vascular death vs 5.83%.68 While a
relative risk reduction of 8.7% was realized, the longitu-
dinal use of a relatively expensive drug may not justify the
cost efficacy vis a vis a modest absolute risk reduction of
less than 1%.
The MATCH study, a randomized, double-blind,
placebo-controlled trial compared aspirin (75 mg once
daily) with placebo in 7599 high-risk patients with recent
ischemic stroke or transient ischemic attack and at least one
additional vascular risk factor who were already receiving
clopidogrel 75 mg once per day. Duration of treatment
and follow-up was 18 months. The primary endpoint was
a composite of ischemic stroke, MI, vascular death, or
rehospitalization for an acute ischemic event. The abso-
lute risk reduction was 1% over that time period. The risk
of life-threatening bleeding was higher in the aspirin and
clopidogrel group (2.6%) vs clopidogrel (1.3%).69
The aforementioned studies demonstrate a benefit to
antiplatelet therapy in the general high-risk vascular popu-
lation, which can be extrapolated to the subset of patients
undergoing CEA. Several studies have also been under-
taken in patients undergoing CEA. Lindblad et al random-
ized 232 patients undergoing CEA to aspirin 75 mg once
daily, starting preoperatively (n  117) to placebo (n 
115). Stroke rates were significantly reduced in those tak-
ing aspirin (2%) vs placebo (9%, P  .01) at 6 months.70 A
further study looking at low-dose aspirin vs placebo started
postoperatively showed a trend toward reduced vascular
events at 2 years.71
A 1999 study randomized over 2700 patients to vary-
ing doses of aspirin (81-1300 mg daily) and examined
stroke, MI, and death at 30 and 90 days after carotid
revascularization.72 Using a composite endpoint, aspirin
doses of 325 mg or less were associated with improved
outcomes at both the 30-day (5.4% vs 7.0%) and 90-day
(6.2% vs 8.4%) time points, compared with the higher dose
regimen. Cervical hematoma rate and systemic bleed com-
plications did not differ between treatment groups. While
caution must be exercised when concluding that higher-dose regimens are deleterious, these data demonstrate the
noninferiority of lower-dose regimens.
To date, there has not been a randomized trial compar-
ing antiplatelet agents and neurologic outcomes in CEA.73
A study from Payne and colleagues demonstrated a poten-
tial benefit to combination (aspirin and clopidogrel) anti-
platelet therapy.74 Patients on combined therapy had a
longer operative time, presumptively because of hemostatic
issues. This did not translate into clinically significant he-
matoma formation or estimated blood loss. Preoperative
clopidogrel in addition to aspirin significantly reduces the
rate of microembolization, conferring a 10-fold reduction
in the relative risk of those patients having 20 emboli in
the postoperative period (OR 10.23, 95% CI, 1.3 - 83.3,
P .01). The clinical relevance of this finding in the larger
population is unknown, but presumptively, these data sug-
gest a mechanism to prevent cognitive decline sometimes
seen after CEA.
A recent publication from the Cochrane Collaboration
reviewed randomized trials looking at the use of antiplatelet
medication after CEA.75 Six trials fit the criteria for entry
into this meta-analysis. Antiplatelet therapy was found to be
significantly protective for the occurrence of stroke (OR 
0.58, CI 0.34-0.98). This study estimated that three out of
100 patients treated with antiplatelet therapy could be
saved from stoke within the follow-up period.
Recent work by the Vascular Study Group of Northern
New England have definitively shown that preoperative
antiplatelet therapy protected against stroke and death
(OR, 0.4;95% CI, 0.2-0.9;P .02) in patients undergoing
CEA. These data were reaffirmed in a multistate Medicare
database proving that antiplatelet therapy is essential to
performing safe carotid surgery and should be considered
as evidence based performance measures.76,77
Based on the rationale that antiplatelet therapy reduces
procedural stroke rate, MI rate, and provides a long-term
cardiovascular event risk reduction, the American College
of Chest Physicians recommends perioperative low-dose
aspirin and lifelong therapy for patients undergoing
CEA.73 The role of other agents and multiagent therapy is
unclear, and thus far, only a theoretical advantage has been
proposed. Despite the recommendations, up to one-third
of patients undergoing CEA are not placed on antiplatelet
therapy preoperatively.78
CONCLUSION
CEA remains the gold standard for stroke-risk reduc-
tion in patients with hemodynamically significant carotid
bifurcation disease. With the adoption of evidence-based
medical therapy, there exists an avenue to optimize the care
of patients with carotid disease, to both improve the stroke-
risk reduction benefit of CEA and the short- and long-term
cardiovascular event rate of this at-risk patient population.
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